Orchid Pharma logo

Orchid Pharma financials and balance sheet

NSE: ORCHPHARMABSE: 524372Pharmaceuticals & BiotechnologySmall Cap

Formerly Orchid Chemicals & Pharmaceuticals
Last close ₹823.30down ₹52.25 (5.97%)BSE ₹826.10

Share price at the NSE close on 23 Oct 2026. Previous close ₹875.55.

52-week range of traded prices to 23 Oct 2026
₹480.00Low, 30 Mar 2026₹1,143.50High, 22 Sep 2026
Market cap
₹4,930 Cr919th largest listed
P/E
Earlier quarters restated in the year
P/B
Shares changed
Dividend yield
Nonein the last 12 months
ROCE
0.2%
Debt to equity
0.19
Volume, NSE
1,70,48053.5% delivered

10 years at a glance

Consolidated: the company and its subsidiaries together. ₹ crore, years to March.Orchid Pharma annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
  • Loss
A loss in 5 of the 10 years shown

Operating and net margin, per cent

  • Operating margin
  • Net margin

The years either side of a change of basis do not compare. From the year to Mar 2021, the company reports a discontinued business. From the year to Mar 2026, the company's revenue for that year, ₹1,233 Cr, differs from its quarters added, ₹942 Cr.

Results for the year to Mar 2026

Consolidated: the company and its subsidiaries together. ₹ crore.

From revenue to net profit

  1. Revenue1,233
  2. Materials and goods−844
  3. Employee costs−118
  4. Other expenses−237
  5. Operating profit34
  6. Depreciation−43
  7. Other income+36
  8. One-off items−7.3
  9. Finance costs−9.0
  10. Profit before tax10
  11. Tax+0.2
  12. Joint ventures−0.7
  13. Net profit10.0

What the company owns

  • Plant, investments and other assets₹1,421 Cr
  • Receivables₹381 Cr
  • Inventory₹372 Cr
  • Cash and bank₹84 Cr

What pays for it: net worth and liabilities

  • Net worth₹1,564 Cr
  • Owed to suppliers₹347 Cr
  • Borrowings₹301 Cr
  • Other liabilities₹46 Cr

Profit and loss

Consolidated, ₹ crore, years to March.Orchid Pharma quarterly results

₹ croreMar 2017Mar 2018Filed 23 AugMar 2019Filed 14 JunMar 2020Filed 3 JulMar 2021Filed 24 MayMar 2022Filed 18 MayMar 2023Filed 17 MayMar 2024Filed 7 JunMar 2025Filed 12 JunMar 2026Filed 14 Aug
Revenue from operations8076886005084505606668199221,233
–6726185344005105827098051,199
Materials and goods bought393350290243229314385484544844
Employee costs–8682856763657086118
Other expenses–236246205105133132155174237
Operating profit before depreciation–16−18−2550508411111734
Operating margin–2.3%−3.0%−5.0%11.1%8.9%12.6%13.5%12.7%2.7%
Materials, % of revenue–50.9%48.3%47.9%50.8%56.0%57.8%59.1%59.0%68.5%
Employee costs, % of revenue–12.5%13.7%16.7%14.9%11.3%9.8%8.5%9.4%9.5%
Other expenses, % of revenue–34.3%41.0%40.4%23.3%23.8%19.9%18.9%18.9%19.2%
Depreciation and amortisation1411331301261098755333543
Operating profit after depreciation–−118−148−151−59−37297783−10
Other income1520172415919312736
Finance costs3313020451323216159
Profit before one-off items and tax–−399−132−131−95−6016929618
One-off items−8602010003900−7
Profit before tax−539−39969−131−95−6055929610
−48−4600000−300
Share of profit of joint ventures and associates––––––−2−34−1
Profit from discontinued businesses––––−2158−7–––
Net profit−490−35369−131−117−2469210010
Other comprehensive income–11−21100−11
Total comprehensive income–−35270−133−116−146929911
Net margin−60.7%−51.3%11.6%−25.8%–––11.2%10.8%0.8%
Net margin without joint ventures and associates–––––––11.6%10.4%0.9%
Operating expenses, operating profit before depreciation and operating profit after depreciation are left blank for the year to Mar 2017: revenue, other income and exceptional items less the total expenses stated do not come to the profit before tax the same statement states, so the operating expenses cannot be told apart from the rest. Net margin is left blank for the years to Mar 2021, Mar 2022 and Mar 2023: the profit includes the result of a business the company has discontinued, which the revenue does not, so the two make no margin.

Balance sheet

Consolidated, ₹ crore, at 31 March.

₹ croreMar 2018Filed 23 AugMar 2019Filed 14 JunMar 2020Filed 3 JulMar 2021Filed 24 MayMar 2022Filed 18 MayMar 2023Filed 17 MayMar 2024Filed 7 JunMar 2025Filed 12 JunMar 2026Filed 14 Aug
−792−7041,0246536476891,1691,2671,564
Share capital898941414141515160
Reserves−881−7939846126076481,1191,2171,504
2,5882,120501430268331134174301
2,0132,343181142241372260286491
1,9051,438516442222165124135203
3,1253,0771,7221,2371,1111,2251,5541,6882,258
2,4462,3791,1346876617247638801,329
679698587429437501791807929
Net debt2,2831,795326395260301−132−5218
Borrowings are counted again inside the liabilities due within a year and after a year. No balance sheet is on record for the year to Mar 2017, so its lines and the ratios worked from it are blank there.

Cash flow

Consolidated, ₹ crore, years to March.

₹ croreMar 2021Filed 24 MayMar 2022Filed 18 MayMar 2023Filed 17 MayMar 2024Filed 7 JunMar 2025Filed 12 JunMar 2026Filed 14 Aug
29891912619126
34325914337115
−3763−8731−10171
Receivables−82−23−4220−42−40
Inventories−333−56−35−6285
Payables18471455−729
Other working capital6136−3−810−4
Tax paid−5−20−1−12
Interest paid0000−170
Capital spending1148565150390
Free cash flow2875−6661−131−264
95116−31−312−27−277
85−2173116725137
Dividends paid000000
Shares bought back000000
Shares issued00039200
Net change in cash209−1118−1918−14
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the years to Mar 2017, Mar 2018, Mar 2019 and Mar 2020.

Per share

Consolidated, ₹ per share, years to March.

₹ per shareMar 2017Mar 2018Filed 23 AugMar 2019Filed 14 JunMar 2020Filed 3 JulMar 2021Filed 24 MayMar 2022Filed 18 MayMar 2023Filed 17 MayMar 2024Filed 7 JunMar 2025Filed 12 JunMar 2026Filed 14 Aug
––––−₹28.55−₹0.48₹11.35₹19.06₹19.65₹1.66
As stated that year−₹55.13−₹39.65₹7.80−₹32.11−₹28.55−₹0.48₹11.35₹19.06₹19.65₹1.66
––––−₹28.55−₹0.48₹11.35₹19.06₹19.65₹1.66
––––₹159.96₹158.61₹168.72₹230.58₹249.86₹261.22
Shareholder yield––––0.0%0.0%0.0%−7.4%0.0%0.0%
Market cap at the year end (₹ crore)2339849–9,8271,1641,5645,2993,9362,447
Every year is restated for later splits and bonuses, so they do not break the line. The figure the company stated that year is under each line it differs from.

Ratios

Consolidated, years to March.Orchid Pharma PE ratio and valuation

RatioMar 2017Mar 2018Filed 23 AugMar 2019Filed 14 JunMar 2020Filed 3 JulMar 2021Filed 24 MayMar 2022Filed 18 MayMar 2023Filed 17 MayMar 2024Filed 7 JunMar 2025Filed 12 JunMar 2026Filed 14 Aug
Revenue growth−7.6%−14.8%−12.8%−15.3%–24.3%19.0%23.0%12.5%–
Operating profit growth–––––−0.3%68.5%32.4%5.9%–
Net profit growth–––––––99.0%8.1%–
Earnings per share growth–––––––67.9%3.1%–
–44.6%−9.3%−81.8%−13.9%−0.3%6.9%9.9%8.2%0.7%
––−53.8 pts−72.6 pts67.9 pts13.6 pts7.2 pts3.0 pts−1.7 pts−7.5 pts
From the net margin––−54.6 pts30.0 pts––––−0.4 pts−7.6 pts
From asset turnover––1.2 pts2.0 pts––––−0.3 pts0.1 pts
From borrowing––−0.4 pts−104.5 pts––––−1.0 pts0.0 pts
Return on capital employed–−6.5%−10.5%−9.9%−5.5%−4.1%2.8%5.9%5.7%−0.5%
Cash conversion––––––40.1%136.7%19.3%1,261.5%
Interest cover––––––0.94.75.7–
Debt to equity–––0.490.660.410.480.120.140.19
Receivable days–6373491101111188796113
Inventory days–202214234244201217199219161
Payable days–374381155176195173173149150
Cash conversion cycle, days–−109−94127179117163113166124
Working capital days–−501−776166207161154124152140
Asset turnover–0.220.190.210.300.480.570.590.570.62
Assets per rupee of net worth–−3.95−4.1514.981.761.811.751.501.331.39
Sales per rupee of plant–0.540.530.500.670.961.161.321.461.80
Capital spending to depreciation––––0.010.171.551.954.359.01
Plant being built, % of plant in use–20.3%23.1%7.6%1.1%1.7%8.1%2.6%10.2%49.6%
Interest cover is left blank for the years to Mar 2018, Mar 2019, Mar 2020, Mar 2021, Mar 2022 and Mar 2026: operating profit after depreciation is a loss, and a loss covers no interest bill. Debt to equity is left blank for the years to Mar 2018 and Mar 2019: net worth is below zero, so there is no shareholders' money to set the borrowings against. From the net margin, from asset turnover and from borrowing are left blank for the years to Mar 2021, Mar 2022, Mar 2023 and Mar 2024: the profit of this year or the year before includes a business the company has discontinued while its revenue does not, so the change in return on equity is not split into margin, turnover and borrowing. Revenue growth is left blank for the year to Mar 2021: between the two periods the company began reporting a business as discontinued, so the two are on different bases and the change is not worked out. Revenue growth, operating profit growth, net profit growth and earnings per share growth are left blank for the year to Mar 2026: between the two periods the company restated its earlier figures, so the two are on different bases and the change is not worked out. No balance sheet is on record for the year to Mar 2017, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Consolidated: the company and its subsidiaries together. Each window ends with the year to Mar 2026.

Return on assets, latest year
0.5%
Cash from operations against operating profit
374.2%
Measure10 years5 years3 years
Revenue growth, yearly rate3.5%22.3%22.8%
Profit growth, yearly rate––−40.1%
Return on equity, average−3.9%5.1%6.3%
Return on capital employed, average−2.5%2.0%3.7%
Operating margin, average6.2%10.1%9.6%
Net margin, average––7.6%
Asset turnover, average0.420.570.59
Cash conversion cycle, days, average87136134
Interest cover, average––5.2
Debt to equity, average–0.270.15

Where the cash came from and went

Consolidated: the company and its subsidiaries together. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore5 years3 yearsLatest year
Cash from operations378271126
Cash from investing−531−616−277
Cash from financing144329137
Capital spending704605390
Dividends paid000
Shares bought back000
Shares issued for cash3923920
Borrowings raised392199170
Borrowings repaid54623223

Accounting checks

Consolidated, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Piotroski score, out of 9Published threshold 3 points out of 9–––466744
Altman Z-scorePublished threshold 1.81−0.77−0.73–11.312.903.4010.457.764.24
Beneish M-scorePublished threshold −1.78–––−1.61−3.05−1.63−2.42−1.75−1.74
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets–––−16.22−17.665.0720.026.628.17
Cash from operations to profit, 3 yearsPublished threshold 0.7 times––––––1.710.691.34
Receivables growth less revenue growthOur threshold 0 percentage points–13.09−27.98111.061.377.16−32.1811.1523.97
Inventory growth less cost-of-goods growthOur threshold 0 percentage points–4.917.744.26−24.299.82−10.4411.18−41.09
Other current assets growth less revenue growthOur threshold 5 per cent of revenue–3.7220.70−18.25−3.61−8.844.63−0.522.64
Assets under construction, years of additionsOur threshold 2 years of additions–118.7412.75–31.231.050.211.373.47
Effective tax ratePublished threshold 17.16 per cent–0.00–––0.00−3.39−0.20−1.84
Tax charged less tax paid, % of profitOur threshold 10 percentage points–––––−0.54−4.08−1.18−24.40
A threshold marked as ours has no published figure; it is the line we read the check against.

Credit ratings

An agency's view of the chance the company repays a borrowing on time, from AAA, the highest, down to D, in default.

DateAgencyBorrowing ratedRatingOutlookAmount, ₹ Cr
8 Apr 2026CARE Ratings Limited (opens in a new tab)Fund-based - LT-Term LoanCARE BBB+Review, DowngradeStable142.50
8 Apr 2026CARE Ratings Limited (opens in a new tab)LT/ST Fund-based/Non-fund-based-CC/WCDL/OD/LC/BGCARE BBB+ / CARE A2Review, DowngradeStable75
8 Apr 2026CARE Ratings Limited (opens in a new tab)Non-fund-based - ST-BG/LCCARE A2Review, Re-affirm84
7 Aug 2025CARE Ratings Limited (opens in a new tab)Fund-based - LT-Cash CreditCARE A- (Rating Watch with Developing Implications)Review, Re-affirm65
The latest rating on each borrowing. The agency's name opens its reasoning for the rating.